A Pilot Study of F-18-Alfatide PET/CT Imaging for Detecting Lymph Node   Metastases in Patients with Non-Small Cell Lung Cancer

doi:10.1038/s41598-017-03296-6

CORC > 北京大学 > 化学与分子工程学院

	A Pilot Study of F-18-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer
	Zhou, Yue ; Gao, Song ; Huang, Yong ; Zheng, Jinsong ; Dong, Yinjun ; Zhang, Baijiang ; Zhao, Shuqiang ; Lu, Hong ; Liu, Zhibo ; Yu, Jinming ; Yuan, Shuanghu
刊名	SCIENTIFIC REPORTS
	2017
关键词	INTEGRIN ALPHA(V)BETA(3) EXPRESSION POSITRON-EMISSION-TOMOGRAPHY ASP RGD PEPTIDE RADIATION-DOSIMETRY BIODISTRIBUTION F-18-AH111585 ANGIOGENESIS AGENT
DOI	10.1038/s41598-017-03296-6
英文摘要	Angiogenesis plays a key role in tumor development and alpha(v)beta(3) integrin are overexpressed on the endothelial cell surface of newly forming vessels. F-18-Alfatide has favorable properties for alpha(v)beta(3) integrin targeting and showed potential for imaging angiogenesis with Positron Emission Tomography (PET)/computed tomography (CT). In this study, 13 patients with non-small cell lung cancer (NSCLC) who underwent F-18-Alfatide PET/CT before surgery were enrolled. The uptake of all dissected lymph nodes (LNs) of F-18-Alfatide were assessed visually and analyzed with a maximum and mean standard uptake value (SUVmax, SUVmean) and SUV ratios. LN metastases were pathologically confirmed and 20 of 196 LNs were malignant. All malignant LNs were successfully visualized on 18F-Alfatide PET/CT in patients and the sensitivity, specificity and accuracy was 100.0%, 94.9% and 95.4%, respectively. SUVmax, SUVmean and SUV ratios in malignant LNs were significantly higher than in benign LNs for NSCLC patients (P < 0.001). The same result was observed in patients with adenocarcinoma and squamous cell carcinoma (P < 0.001). The F-18-Alfatide parameter shows high sensitivity (83.9-100%), specificity (78.6-96.7%) and accuracy (81.7-96.9%) according to thresholds calculated from receiver operating characteristic curve. Our results suggest that F-18-Alfatide PET/CT is valuable in the diagnosis of metastatic LNs for NSCLC patients.; Natural Science Foundation of China [NSFC81372413, NSFC81172133]; special fund for Scientific Research in the Public Interest [201402011]; Outstanding Youth Natural Science Foundation of Shandong Province [JQ201423]; projects of medical and health technology development program in Shandong province [2014WS0058]; SCI(E); ARTICLE; 7
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/472878]
专题	化学与分子工程学院
推荐引用方式 GB/T 7714	Zhou, Yue,Gao, Song,Huang, Yong,et al. A Pilot Study of F-18-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer[J]. SCIENTIFIC REPORTS,2017.
APA	Zhou, Yue.,Gao, Song.,Huang, Yong.,Zheng, Jinsong.,Dong, Yinjun.,...&Yuan, Shuanghu.(2017).A Pilot Study of F-18-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer.SCIENTIFIC REPORTS.
MLA	Zhou, Yue,et al."A Pilot Study of F-18-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer".SCIENTIFIC REPORTS (2017).